Amylyx is a pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders.
Amylyx is a pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. They incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors, and organizations by working collaboratively across everything they do to positively impact the lives of patients and their families.
Kineticos Venture Partner, Derek Hennecke, has served as an investor and strategic advisor since the seed stage of Amylyx.
Team: Executives and advisors are experts within Neurosciences and key opinion leaders in the market
Platform: Novel combination therapy with compelling clinical data showing improvement in patients with ALS
Unmet Need: Neurodegenerative disorders, particularly ALS, have poor treatment options, with nearly 9000 ALS patients per year
Arranta Bio is a microbiome and mRNA CDMO that provides novel solutions to clients for advanced therapy process development and manufacturing.
Arranta Bio is a CDMO that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies such as microbiome and RNA-based therapies. The dedicated team, state-of-the-art facilities, and unparalleled resources are crucial for advancing products from development to commercial launch. Arranta Bio was founded by Kineticos Venture and Operating Partner Mark Bamforth.
Shailesh Maingi, Kineticos Ventures GP member, joined the board of directors during the Series A financing until the acquisition of Arranta Bio by Recipharm in April 2022. Kineticos, through its consulting arm, supported Arranta Bio with multiple market assessments and primary research studies prior to the Series A financing and to develop and execute on their strategy.
Team: Comprised of entrepreneurial and scientific veterans
Platform: Live Biotherapeutic Products (LBPs), pDNA, and mRNA vaccine cGMP manufacturing with multiple facilities
Unmet Need: microbiome dysbiosis is linked to infectious, gut, and neurological diseases and cancer therapy effectiveness. pDNA is a critical raw material for gene therapies. mRNA vaccines have shown efficacy in oncology therapeutics
Visit Site
DIANT® Pharma Inc. was founded in 2019 and has developed continuous processing technology for nanoparticles.
DIANT® Pharma Inc. (Manchester, CT USA) was founded in 2019 and has developed continuous processing technology for nanoparticles. DIANT is dedicated to bringing advanced, continuous manufacturing technology to the market and to providing R&D services. Their proprietary, continuous manufacturing system for nanoparticles has a wide array of applications within the pharmaceutical space.
DIANT is an equipment company with a continuous manufacturing technology for Lipid Nanoparticles (“LNP”) and nanoparticle drug product development. DIANT’s equipment is a single-jet, scalable technology with end-to-end manufacturing capabilities of various types of nanoparticles, including liposomes, LNP, Polymeric Micelles, Emulsions, Suspensions, and others.
Visit Site
Endolytix is using enzymes from bacteriophages to target antibiotic resistant nontuberculous mycobacteria (NTM) that cause chronic lung disease.
Endolytix is developing a therapy to treat non-tuberculous mycobacterial pulmonary disease (NTM-PD). NTM-PD is a difficult to treat chronic respiratory disease characterized by high rates of recurrence. There is a need for new therapies to disrupt the standard of care as the current treatment regimen has poor efficacy and tolerability that limits the number of eligible patients, while also having 12+ month treatment timelines. During infection, NTMs target and infect macrophages in the lung, allowing them to hide from the immune system and antibiotics. Endolytix’s approach utilizes a cocktail of phage lysins delivered in proprietary inhaled liposome formulations that can target macrophages and the pathogens hiding within them.
Visit Site
EnteroBiotix is a clinical-stage Microbiome biotech focused on developing therapeutics for Hepatic Encephalopathy and Graft vs. Host Disease.
EnteroBiotix (“EBX”) is a clinical-stage Microbiome biotech focused on developing therapeutics for Hepatic Encephalopathy (“HE”) and Graft vs. Host Disease (“GvHD”). EBX has a GMP-grade manufacturing facility and was approved by the Medicines and Healthcare products Regulatory Agency (“MHRA”).
Visit Site
eXmoor pharma is a one-stop cell and gene therapy partner accelerating the manufacturing journey from research to patients.
eXmoor pharma is a one-stop cell and gene therapy partner accelerating the manufacturing journey from research to patients. Founded in 2004, eXmoor has specialized in the CGT sector since 2007 helping organizations to understand, plan and implement the appropriate CMC strategy. eXmoor does this via its translation and capital consulting groups, process and analytical development labs and now GMP manufacturing capability.
Experic is a CDMO and pharmaceutical supply services company.
Experic is a CDMO and pharmaceutical supply services company. Experic supports every phase of a product’s life cycle from clinical to commercial scale across a range of dosing and packaging formats, including capsule filling, powder and pellet dosing (including DPI), and autoinjectors and pen assemblies.
Visit Site
FastBack Bio is a biotechnology company with a novel CAR-T platform. FastBack Bio will develop CAR-T therapeutics with a novel co-stimulatory domain, M83, from its in-licensed platform.
FastBack Bio is a biotechnology company with a novel CAR-T platform. FastBack Bio will develop CAR-T therapeutics with a novel co-stimulatory domain, M83, from its in-licensed platform. The M83 technology is an alternative to the more commonly used co-stimulatory domains, CD28 and 4-1BB. In vitro experiments indicate that M83 provides CAR-T with cells enhanced expansion kinetics, a balance of effector and central memory phenotypes, and resistance to T cell exhaustion. In vivo solid tumor murine models demonstrate that M83-based CAR-T cells have enhanced tumor-killing capabilities and are superior to both CD28- and 4-1BB-based CAR-T cells.
Visit Site
Inceptor Bio is developing next-generation cell therapy programs with a focus on chimeric antigen receptor (CAR) constructs.
Inceptor Bio is developing next-generation cell therapy programs with a focus on chimeric antigen receptor (CAR) constructs, which have novel mechanisms to enhance immune cell activation and endurance in the tumor microenvironment (TME). Inceptor Bio provides best-in-class therapies – CAR-T, CAR-M, CAR-NK platform technologies – to enhance the likelihood of success against difficult-to-treat cancers.
Kineticos, through its consulting arm, has supported various strategy, business development, and scientific consulting projects throughout the growth of Inceptor Bio. Inceptor Bio was founded by Shailesh Maingi, Kineticos Ventures GP member. Inceptor Bio’s team, board of advisors, and scientific advisory board members consist of Kineticos Ventures Operating Partners, Venture Partners, and Strategic Advisors.
Team: Leading scientists and executives in Cell and Gene Therapy
Platform: CAR-T, CAR-M, CAR-NK utilizing novel technology platforms licensed from top research universities
Unmet Need: Cancer is the leading cause of death, responsible for 1 out of 6 deaths
Kincell is a technology-forward contract development and manufacturing organization (CDMO).
Kincell Bio engineers cell into therapies. Headquartered in Gainesville, Fla., Kincell is a technology-forward contract development and manufacturing organization (CDMO) formed to streamline analytical development, process development, CMC consulting and early-stage GMP cell therapy manufacturing. Kincell’s initial focus is on manufacturing commercially viable immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK, and CAR-M programs.
Visit Site
neuro42, Inc. is a medtech Company advancing futuristic technologies for screening, diagnosis, and targeted treatment of neurological conditions.
neuro42, Inc. is a medtech Company advancing futuristic technologies for screening, diagnosis, and targeted treatment of neurological conditions. The Company is developing and commercializing a portable MRI, robotic and AI platform, backed by over 30 patents, for point-of-care imaging and interventions under live image guidance. neuro42 is founded by a team of serial entrepreneurs and innovators with a mission to improve lives through its patient-centric solutions.
Visit Site
Orthobond has developed a coating for medical device implants to prevent biofilm formation and infection from orthopedic surgery.
Orthobond has pioneered a groundbreaking method to permanently alter the surfaces of metal and polymer medical devices to destroy bacteria that contact these surfaces during implant surgery, distinguishing itself from conventional approaches that often face resistance issues. Unlike drug classified solutions that may contribute to bacterial resistance, Orthobond’s technology ensures broad-spectrum antimicrobial activity without these challenges because it does not utilize an antibiotic drug. This innovation is crucial given the heightened risk of infections from bacteria colonizing implant devices, which are significantly more resistant than free-floating bacteria. Orthobond’s solution, Ostaguard, features a polycationic surface that attracts and destroys bacteria by binding to their negatively charged peptidoglycan layer, causing membrane destabilization and intracellular leakage. This nanoscale attack prevents biofilm formation, a common issue with implants.
Visit Site
Promaxo develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients’ lives and redefine the standard of care.
Promaxo develops and commercializes customer-centric MRI systems and MRI-based technologies that enhance patients’ lives and redefine the standard of care.
The Promaxo MRI system is an open MRI system to image the internal structures of the body. The system is designed for a physician’s office without considerable facility upgrades.
Visit Site